SSTR2 and central nervous system cancer: We have recently demonstrated that PET/CT imaging with intravenously injected 68Ga-DOTA-peptide targeting SSTR2 provides limited value in defining suitable patients with high-grade glioma for targeted radionuclide therapy [16].